Presentation Of Citrullinated Peptides Derived From Unmodified Protein By Antigen Presenting Cells. by Rimer, Jamie
Washington University in St. Louis
Washington University Open Scholarship
All Theses and Dissertations (ETDs)
5-24-2010
Presentation Of Citrullinated Peptides Derived
From Unmodified Protein By Antigen Presenting
Cells.
Jamie Rimer
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/etd
This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All
Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.
Recommended Citation
Rimer, Jamie, "Presentation Of Citrullinated Peptides Derived From Unmodified Protein By Antigen Presenting Cells." (2010). All
Theses and Dissertations (ETDs). 874.
https://openscholarship.wustl.edu/etd/874
  
 
 
WASHINGTON UNIVERSITY IN ST. LOUIS 
Division of Biology and Biomedical Sciences 
Program in Immunology 
 
Dissertation Examination Committee: 
Paul Allen, Chair 
John Atkinson 
Ted Hansen 
Barry Sleckman 
Wayne Yokoyama 
Emil Unanue 
 
PRESENTATION OF CITRULLINATED PEPTIDES DERIVED FROM 
UNMODIFIED PROTEIN BY ANTIGEN PRESENTING CELLS. 
by 
Jamie Michelle Rimer 
 
 
A dissertation presented to the 
Graduate School of Arts and Sciences 
of Washington University in 
partial fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 
 
December 2010 
Saint Louis, Missouri 
 
 ABSTRACT OF THE DISSERTATION 
Presentation of citrullinated peptides derived from unmodified protein by 
antigen presenting cells. 
By 
Jamie Michelle Rimer 
Doctor of Philosophy in Biology and Biomedical Sciences 
(Immunology) 
Washington University in St. Louis 2010 
Professor Emil R. Unanue, Chair 
Autoimmune responses to citrullinated proteins have been associated with 
rheumatoid arthritis; however, little is known of the mechanism by which 
tolerance to citrullinated proteins is established or the biology of citrullination by 
cells of the immune system.  
We find that immunization of B10.BR mice with HEL in CFA gives rise to T 
cells that specifically recognize citrullinated epitopes. We generated T cell 
hybridomas by fusing these T cells. T cell hybridomas that recognize citrullinated 
peptides from hen egg white lysozyme (HEL) were used to detect presentation of 
citrullinated peptides. Using this technique, we show that antigen presenting cells 
(APC) present citrullinated peptides after processing whole unmodified protein.   
As expected, APC isolated from the draining lymph node of mice 
immunized with HEL in complete Freund's adjuvant elicit a response from the 
citrullinated peptide specific T cell hybridomas. Examination of APC from HEL 
transgenic mice revealed that splenic dendritic cells, macrophages and thymic 
dendritic cells presented citrullinated peptides constitutively. Conversely we did 
ii 
 
 not detect a response from B cells pulsed with HEL or from HEL transgenic mice 
or from a B lymphoma line. 
The reported localization of the enzymes that convert peptidylarginine to 
peptidylcitrulline is either the cytosol or nucleus and not in antigen processing 
and loading compartments. The role of autophagy, or the mechanism by which 
cytosolic proteins and senescent organelles are taken up in to vesicles for 
degradation in lysosomes, in citrullination of antigen was examined. 
Treatment of dendritic cells and macrophages with 3-Methyladenine 
(3MA), a class III PI3 kinase inhibitor known to inhibit autophagy, blocked 
presentation of citrullinated peptides but presentation of unmodified peptides was 
not affected.  
B cell receptor engagement has been shown to induce autophagy in 
primary B cells. We examined presentation of HEL by B cells from anti-HEL 
transgenic mice, in which all B cell receptors bind HEL, and found that, in 
contrast to B cells from B10.BR mice, they presented citrullinated peptides. B 
cells from mHEL mice present citrullinated peptides after BCR engagement with 
anti-IgM or anti-IgG antibodies. Induced presentation of citrullinated peptides was 
blocked by 3MA.  
In addition, we find that C3.F6.mHEL B lymphoma cells present 
citrullinated peptides after serum starvation but blocked by 3MA treatment. 
C3.F6.mHEL cells that stably expressed shRNA targeting Atg5, a protein 
essential for autophagy, did not present citrullinated peptides after serum 
starvation. Higher levels of citrulline in naturally processed peptides from these 
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 cells were detected biochemically after culture in serum starved conditions. Our 
findings demonstrate a role for autophagy in citrullination of antigen during 
processing by antigen presenting cells. 
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 CHAPTER 1 
INTRODUCTION 
 
Citrullination and Peptidylarginine deiminase  
 
 The process by which the immune system establishes tolerance to self-
proteins bearing post-translational modifications is poorly understood. One post-
translational modification, citrullination, has been implicated in the 
pathophysiology of two autoimmune diseases, rheumatoid arthritis and multiple 
sclerosis [1-6]. This body of work examines the ability of antigen presenting cells 
to impart this modification on protein antigen while processing for presentation on 
MHC class II.  In this section, we will review what is known about citrullination in 
normal biology as well as the evidence for a role for citrullination in autoimmunity.  
 
Citrullination 
 
Citrulline is not a natural amino acid encoded in DNA and there is no tRNA 
specific to this amino acid. It was first described in 1914 when it was isolated 
from watermelon by Koga and Odake in Japan and in 1932 found by Krebs and 
Henseleit to be an intermediary of the urea cycle. Citrulline is not incorporated 
into proteins as they are synthesized. Citrulline in proteins was first described in 
1930 by another Japanese group who described its presence in tryptic digests of 
caseinogen (Wada 1930). The presence of citrulline in proteins is due to the 
 
 enzymatic deimination of arginine residues in a process called citrullination. 
Citrullination is the hydrolytic deimination of arginine residues to yield ammonia 
and peptidylcitrulline. The change from arginine to citrulline leads to a net loss of 
one atomic mass unit and a loss of positive charge. Citrulline lacks the strongly 
basic character of arginine and is a neutral amino acid similar to glutamine. The 
loss of positive charge leads to altered inter and intra-molecular interactions and 
the functional consequences of this change have many important roles in normal 
biology [7, 8]. The detection of citrulline in biological samples has been largely 
facilitated by chemical derivatization of the ureido functional group of citrulline [9] 
that leads to the formation of a colored product.   
 
Peptidylarginine deiminase 
 
A family of proteins called peptidylarginine deiminases catalyzes this 
reaction [10-16]. There are five PAD isoform that have been identified (EC 
3.5.3.15). The genes are clustered on chromosome 1p35-36 and conserved with 
synteny on mouse chromosome 4E1. The substrate specificity of these enzymes 
seems to be limited and the activity of the enzymes is regulated by the 
requirement for high calcium levels as well as by expression. The tissue 
expression of these proteins has been characterized. PAD2 is ubiquitously 
expressed. PAD1 and 3 are found in the skin and hair follicles as well as in the 
uterus. PAD4 is expressed by cells of the immune system. PAD6 is found in 
eggs, ovaries and early embryos. [17-24] These enzymes require high levels of 
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 calcium (10-5 M) for biological function due to 3 conserved calcium binding sites 
that when bound induce a conformational change that reveal the active site and 
allow substrate binding [25]. The mechanism by which this enzyme catalyzes this 
reaction has been proposed by two independent groups.  Arita proposed that the 
cysteine attacks the guanidino group and acts as a tetrahedral adduct while 
ammonia is released. A water molecule then acts as a nucleophile and attacks 
the adduct, releasing the regenerated cysteine and forming a ureido group [25]. 
In agreement with this report, Paul Thompson’s laboratory introduced a series of 
mutations to provide evidence for a reverse protonation reaction in which the 
active site cysteine exists as a thiolate that is stabilized by forming an ion pair 
with a nearby histidine [26].  
 
PAD Isoforms and roles for citrullination in biological processes. 
PAD1, 2, &3- Hair and Skin 
 
Perhaps the most well studied processes, as well as one of the earliest 
described roles for this post translational modification, are those of the 
cornification of skin and the hardening of the hair follicle.  
The presence of citrulline in hair was described in 1962 by Rogers et al 
[27], who later went on to report that it was a Calcium dependent enzymatic 
activity that lead to the presence of citrulline in these proteins [28, 29]. The major 
citrullinated protein in the inner root sheath was found to be trichohyalin. 
Deimination of trychohyalin by PADs 1and 3 increases its solubility, releasing it 
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 from the trychohyalin granules and allowing it to be linked to type1 keratins by 
transglutminases [8, 21]. 
In the epidermis, PAD enzymes 1, 2, and 3 are expressed and are 
involved in terminal cornification as well as maintenance of healthy skin through 
its role in the production of natural moisturizing factor. Deimination of the basic 
Keratin K1 and thus the loss of positive charge occurs during the process of 
differentiation from keratinocyte to corneocyte [30] and it is speculated that this 
alters the interaction with the acidic keratin K10, which is also deiminated, and 
facilitates relaxation of the corneocyte fibrous matrix [31]. In addition to Keratin in 
the skin, filaggrin is also deiminated. Filaggrin is synthesized as a profilaggrin, a 
large molecule that upon differentiation is deiminated and cleaved into individual 
filaggrin units which can then act to bundle keratin filaments into an organized 
matrix (Pearton 2002). Citrullination of filaggrin leads to increased susceptibility 
to proteolysis and allows it to be cleaved into amino acids that make up natural 
moisturizing factor [32] [33] [16]. 
 
Apoptosis 
 
 Citrullination may play an important role in apoptosis. Intermediate 
filaments are more stable than the dynamic microfilaments and the regulation of 
their polymerization has yet to be worked out. The arginine residues in vimentin, 
an intermediate filament expressed in various cell types, are required for 
polymerization. In vitro citrullination of vimentin filaments causes disassembly 
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 [34, 35]. During apoptosis, where cytosolic calcium levels are very high, PAD 
enzymes deiminate vimentin and may be involved in apoptotic morphological 
changes [35]. 
 In addition to regulating intermediate filament disassembly during cell 
death, citrullination may have a role in the induction of apoptosis. Over-
expression of PAD4 in cell lines induced apoptosis through increased P53 and 
mitochondrial membrane depolarization[36]. Deimination of histones H2A, H3, 
H4 and nucleophosmin/B23 may alter chromatin organization and DNA 
susceptibility to fragmentation. This may lead to the induction of apoptosis 
through DNA damage signals as well as play a role in DNA fragmentation during 
apoptosis [22, 37, 38]. In cells undergoing calcium ionophore induced apoptosis, 
70kDa nuclear protein associated with the nuclear lamina was found to be 
deiminated [39]. Citrullination of this protein reduced its isoelectric point and 
reduced its affinity for the inner nuclear membrane, which contributes to the 
degeneration of the nuclear lamina during apoptosis.   
 
Myelin Basic Protein 
 
 PAD2 and PAD4 are expressed in the central nervous system [4, 40-44]. 
Myelin basic protein (MBP) is expressed by oligodendroglial cells and is a key 
component of the myelin sheath. It associates with lipids through ionic 
interactions and acts to help organize the lipids into compact multi-layered 
structures. There are several isoforms of MBP that undergo various 
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 posttranslational modifications including citrullination [45]. These modifications 
regulate the strength of the interactions between the positively charged MBP and 
the negatively charged lipids [4, 41]. Posttranslational modifications of the 
different isoforms of MBP produce different charge isomers and this influenced 
the fluidity of the myelin sheath [46-48]. The ratio of deiminated MBP to total 
MBP is important for CNS function [49] and it changes through development of 
the central nervous system. In humans for the first two years nearly all of the 
MBP is deiminated [50-52] and the ratio of citrullinated MBP to MBP gradually 
goes down until the age of four where it remains at about 18%. This change 
corresponds to decreased plasticity of the brain as it develops. In addition, the 
areas of the CNS associated with more rudimentary function have been shown to 
have higher levels of citrullinated MBP [53].  
 
Epigenetic regulation of gene expression 
 
PAD4 is the only PAD isoform that can localize to the nucleus and does so 
by virtue of a monopartite nuclear localization signal [22]. Posttranslational 
modification of histones is a mechnism by which gene expression is regulated. 
The most well known histone modifications are methylation, acteylation and 
deacteylation [54-56]. PAD4 is also involved in chromatin remodeling. This 
enzyme has been shown to deiminate nuclear proteins including histones H2A, 
H3 H4 and nucleophosmin/B23 and has been shown to regulate gene expression 
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 by this mechanism. In addition, hypercitrullinated histones have been detected in 
decondensed chromatin [57, 58].  
It had previously been thought that histone methylation was an irreversible 
process as no histone demethylating proteins had been identified [59]. However 
PAD4 has been shown to be able to reverse histone methylation by converting 
arginine to citrulline and releasing methylamine [57].  
PAD4 expression in the uterus and pituitary gland was shown to be 
dependent on expression of 17β-estradiol [60]. Interestingly, PAD4 acts as a 
transcriptional corepressor of estrogen responsive genes. Activation of estrogen 
responsive genes is partially due to the methyltransferase activity of CARM1 and 
PRMT1, which methylate histones and enhance gene expression [61, 62]. Wang 
et al. showed that these histones (specifically at the pS2 gene) were methylated 
in MCF-7 cells treated with estrogen and a concomitant increase in expression 
was observed. However after 40-60 minutes the amount of PAD4 at these sites 
doubled and citrullination at these sites was observed and coincided with 
transcriptional silencing [57]. There is specificity to PAD4 transcriptional silencing 
as no PAD4 was observed at control genes. It is not clear what mediates this 
specificity. One recent paper from the Fuks group has found that PAD4 
physically associates with histone deacetylase1 and that these two proteins 
collaborate to regulate the cyclical expression of estrogen responsive genes [63].  
 
7 
 
 Citrullination and Disease 
Rheumatoid Arthritis 
 
Autoantibodies to self proteins have long been used as a diagnostic 
marker for rheumatoid arthritis. One of the most compelling findings linking 
responses to post-translationally modified self-proteins to autoimmunity is the 
antibody response to citrullinated proteins in RA. Antibodies to self-antigens, 
previously known as anti-perinuclear factor [64] [65] [66], anti-keratin [67] [68] 
[69] antibodies , and anti-Sa antigen [70] have been found in patients with RA 
and were later shown to recognize citrullinated proteins [71, 72], specifically 
fillagrin, fibrinogen [73, 74] and vimentin [75]. A cyclic peptide derived from 
filaggrin has been used as an antigen in an ELISA used in clinical practice to 
diagnose RA with high specificity [76]. These anti-cyclic citrullinated peptide (anti-
CCP) antibodies can be found early in disease and levels can be correlated with 
disease severity [77] [78] [79, 80] [77-79, 81] [7, 82]. Their concentration is higher 
in the arthritic synovium, which possibly reflects a local ongoing antigen driven 
immune response [83] [84, 85]. These results are highly suggestive that a 
response to a citrullinated antigen could be playing a role in the disease process.  
A report by the Holers group demonstrated that in the collagen induced 
arthritis model there are anti CCP antibodies that develop with the same kinetics 
as antibodies to Type II collagen and appear before joint inflammation.  In 
addition, they were able to partially tolerize mice with a peptide derived from 
human fillagrin containing one citrulline substitution, while the unmodified peptide 
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 had no effect. They identified monoclonal antibodies that bound citrullinated 
fibrinogen as well as other citrullinated proteins. When they transferred these 
antibodies into mice that had been given a submaximal dose of a cocktail of 
monoclonal antibodies against type II collagen (Arthrogen) they found that the 
mice developed a more severe disease. Transfer of the antibodies was also able 
to overcome the tolerizing effect of the citrulline containing peptide. They showed 
that there was an increase in citrullination of proteins in the synovium of mice 
with CIA. They observed an increase in citrullinated protein in the lymph nodes of 
mice with CIA. They concluded that presentation of citrullinated antigen in the 
lymph node was driving the generation of the antibodies though they did not 
evaluate how this might occur. They speculated that PAD enzymes might be 
released by infiltrating neutrophils or macrophages, leading to citrullination of 
antigen [86]. 
There is a strong association between the presence of the shared epitope 
(SE) and development of anti-CCP antibodies [87, 88]. Hill et al. showed that 
peptides derived from vimentin with citrulline substitutions at residues that lie in 
the P4 pocket of MHC containing the shared epitope had a much higher affinity 
than the same peptide with arginine at that position. Further, they found that 
immunization with citrullinated peptides in CFA elicited bulk T cell responses 
while immunization with unmodified peptide did not, which suggested that the 
mice were not tolerant to citrullinated vimentin [89].  
In more recent work, Hill et al. demonstrated that immunization of DR4 
transgenic mice with citrullinated fibrinogen, but not unmodified fibrinogen 
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 induced an arthritis-like disease. Control mice (C57Bl/6) were not susceptible, 
suggesting that the HLA transgene played a key role in the response to 
citrullinated proteins. There was a notable difference in the pathology of these 
mice in that there was no infiltration of polymorphonuclear cells. They examined 
T cell specificity based on peptides of fibrinogen that were predicted to bind to 
HLA DR4 and found T cells that were reactive to citrullinated peptides [90]. This 
study represents an attempt to directly show that there is a lack of tolerance to 
neoepitopes generated by citrullination of antigen. However, a major caveat to 
this conclusion comes from studies that demonstrate that derivatization of protein 
antigen can break tolerance [91, 92]; much in the same way that Type B 
responses to self antigen are achieved [93, 94]. It may be that the process of 
citrullination of fibrinogen denatures the protein [8] rendering it available for 
presentation in a less stable conformation and priming responses of T cells that 
have escaped negative selection. Nevertheless, this report is intriguing and the 
results merit further study. The notion that citrullination of self-antigen represents 
a mechanism by which tolerance can be breached is attractive because it 
provides a simple explanation for a potential cause of RA. However, as this 
report demonstrates, this idea is a gross oversimplification of a very complex 
process that likely has many contributing factors. A basic understanding of the 
biology of citrullination within the cells of the immune system is necessary to fully 
begin to understand what role if any this may play in the autoimmune process. 
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 Multiple Sclerosis  
 
Multiple sclerosis (MS) is a debilitating chronic progressive disease that is 
characterized by the destruction of the myelin sheath. This leads to a deficiency 
in saltatory conduction that contributes to the neurological symptoms 
experiences by patients with MS. As the disease progresses there is eventual 
axonal destruction and this leads to paralysis and ultimately death [95, 96].  
The underlying cause of MS is unknown; however the disease is marked 
by lymphocytic infiltration accompanied by macrophages microglia and 
astrocytes suggesting an autoimmune component [97]. In addition there is some 
evidence to suggest that primary neurodegeneration is followed by an 
autoimmune response [98-101] Citrullination has been implicated in both of these 
aspects of the etiology of MS. 
MBP citrullination influences the strength of the interactions with the 
membrane and fluidity of the myelin sheath (See above). It has been reported 
that there is an increase in the amount of citrullination in MS lesions and that 
levels of citrullinated MBP and glial fibrillary acidic protein (GFAP- an 
intermediate filament) can be correlated to the severity of the disease [44] [50] 
[102]. MBP that is heavily citrullinated cannot organize the compact multi-layered 
lipid structures that are a key component of the myelin sheath [103] due to the 
alteration of the electrostatic interactions between the lipid bilayer and the 
charged MBP. This leads to a decrease in the stability of the multi-layered lipid 
structure of the myelin sheath [4, 41]. In addition, MBP that is citrullinated has a 
11 
 
 looser and more disordered conformation and is therefore more susceptible to 
degradation by myelin associated proteases, specifically Cathepsin D. [104] [8] 
[48] [41]. These observations have also been seen in the murine autoimmune 
model of MS, experimental allergic encephalomyelitis (EAE) [105] [106] as well 
as in DM20 transgenic mice, a model for degenerative demyelination [107].  
 Both PAD2 and PAD4 have been found to be expressed in the CNS. 
PAD2 is expressed in oligodendroglial cells, astrocytes, and microglial cells. 
PAD4 can also be detected in the brain and was recently shown to be detected in 
both the cytoplasm and the nucleus of oligodendroglial cells. PAD2 [42] and 
PAD4 [108] expression levels are higher in diseased brain, both in human MS 
and murine EAE. Interestingly, PAD2 knockout mice are still susceptible to EAE 
[109, 110]. PAD4 is active in these mice and can be localized to the target cells 
and citrullination of MBP still occurs although at fewer sites in the protein [42].  
 The immunological aspects of MS indicate that an autoimmune 
component may be involved. The similarities between EAE, a T cell mediated 
disease and MS provide some clues to the autoimmune process that may be 
occurring in MS. The pathology of the MS plaque includes a robust inflammatory 
infiltrate that includes T lymphocytes [101, 111].   MBP has been identified as a 
candidate autoantigen in MS [112, 113]and T cells that recognize MBP have 
been isolated from peripheral blood of patients with MS [114-116]. The 
degradation of citrullinated MBP by Cathepsin D releases an immunogenic 
peptide [43, 117]. 
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  As in the case with RA, it has been speculated that citrullination increases 
immunogenicity of self-proteins and therefore has some role in the pathogenesis 
of MS. The evidence for this comes from the isolation of T cell lines from patients 
with MS and normal controls that were shown to recognize citrullinated MBP 
[118]. More recent work from the same group has elaborated on this finding 
[119]. They evaluated 5 subject pairs of one healthy control and one MS patient. 
Peripheral blood lymphocytes were cultured with MBP-C8 (citrullinated MBP) and 
recall responses to either MBP-C1 (unmodified MBP) or MBP-C8 were assessed. 
They found that in each pair the MS patients had a higher stimulation index, a 
higher number of reactive T cells, or both.  These findings indicate that T cell 
responses to citrullinated MBP are elevated in patients with MS but still present 
in healthy controls. As in the case with RA, the foundational understanding of the 
biological roles for citrullination in the immune system must be established before 
questions of tolerance can properly be addressed. 
 
Autophagy and Antigen Presentation 
 
 Autophagy is a ubiquitous catabolic process by which cytosolic 
components are shuttled in to vesicular compartments for degradation in 
lysosomes. This process has been conserved through evolution and is involved 
in the homeostatic degradation of cytosolic proteins and turnover of senescent 
organelles [120-128].  The extra cellular signals that lead to the initiation of 
autophagy include growth factor removal, amino acid starvation, infection, DNA 
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 damage, and ER-stress among many others. This is in addition to the constitutive 
autophagy that cells undergo to maintain homeostasis. The intra cellular cascade 
that initiates and mediates autophagy is very complex and includes a growing 
number of proteins most of which have been named Atg proteins.  
 The autophagosomal membrane has been suggested to derive from a 
poorly characterized organelle called the phagophore [129-132]. The formation of 
the of the phagophore is dependent on a class III phosphoinositide 3-kinase, 
Vps34, that forms a part of a large complex made of several proteins including 
Atg6 (also called Beclin 1), Atg14 and Atg15. This complex is required for the 
generation of the nascent autophagosome [133-135]. Vps34 is the target of 
chemical inhibition of autophagy by treatment with 3-Methyladenine and 
wortmannin [136].  
There are two ubiquitin-like conjugation systems that converge on the 
formation of a fully formed autophagic vesicle, the Atg12/5 and the Atg8/PE 
systems.  The process of extending the phagophore into a vesicle, or elongation, 
starts with Atg12 conjugation to Atg5 by Atg7 (E1-like). The Atg12/5 complex 
remains only until the autophagosome is formed and then dissociates. This 
complex associates with Atg16L [137, 138]. Microtubule–associated protein 1 
light chain 3 (LC3- also known as Atg8) is the major player in the second 
conjugation system. The 23 amino acids at the C-terminus of LC3 are cleaved by 
the cysteine protease Atg4 leaving an exposed glycine residue and forming LC3I. 
This is then modified by a series of interactions with Atg3 and Atg7 to form LC3II 
16 (kDa) and ultimately conjugated to phosphatidylethanolamine [139]. LC3 
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 remains associated with the autophagosome and is the only known marker 
specific for the autophagic vesicle. 
The observation that peptides from cytosolic sources were presented on 
MHC class II is not a new one. In 1993 Brooks et al. reported that APC 
expressing cytosolic HEL could elicit responses from 3A9 [140]. Brazil in 1997 
showed that C5 could be presented to T cell if excessive degradation was 
prevented by treatment with low doses of the lysosomotropic agent ammonium 
chloride. Furthermore they showed that inhibition of autophagy with 3MA blocked 
this presentation [141]. Studies evaluating naturally processed peptides from 
MHC II molecules have revealed that peptides derived from cytosolic proteins are 
presented at significant levels [142] [143] [144] [145] [146]. This was directly 
addressed in a study by Dengjel et al. that evaluated the repertoire of naturally 
processed peptides isolated from cells that had been treated to induce 
autophagy. In addition to showing a marked increase in the amount of peptides 
derived from cytosolic sources, they also reported an effect of starvation on 
peptides from the same source proteins and found a decrease in the activity of 
various cathepsins in the starved cells indicating that starvation may have some 
effect on MHC II processing [147]. Nimmerjahn et al., using EBV transformed B 
cells expressin cytosolic and renal cell carcinomas that expressed cytosolic 
neomycin phosphotransferase, demonstrated presentation to T cells through 
autophagy as inhibition with 3MA blocked presentation. They excluded cytosolic 
processing by using inhibitors of Class I processing and directly showed the 
protein in endosomes and lysosomes by western blots of subcellular fractions 
15 
 
 [148]. Paludan et al. showed that presentation of a viral nuclear antigen was 
dependent on autophagy, indicating that nuclear components can access 
autophagic compartments [149]. 
It is clear based on these studies that autophagy contributes to antigen 
loading compartments. Work by Dorothy Schmid evaluated the prevalence of this 
in various APC and found that there was continuous input from autophagic 
compartments into MCH II processing vesicles in dendritic cells, macrophages, B 
cells, and Class II positive eptithelial cells. Interestingly they were able to 
strikingly enhance presentation of a protein by targeting it to the autophagosome 
via fusion to LC3.  
In mice that express a green fluorescent protein LC3 fusion it was found 
that thymic epithelial cells have a relatively high level of constitutive autophagy. 
Thymi taken from embryonic Atg5 knock out or control mice were transplanted in 
to the kidneys of wild type mice. Using a series of T cell receptor transgenic mice 
they found differences in positive selection for CD4 T cells but not in CD8 T cells. 
These thymi were transplanted in to athymic nude mice and it was found that 
recipients of Atg5 knock out thymi developed a severe multi-organ autoimmunity. 
This disease was transferable by adoptive transfer of T cells [150].  
This report shows that autophagic contribution to the MHCII peptide 
repertoire in the thymus is involved in the T cell selection and plays a significant 
role in the deletion of autoreactive T cells.   
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 CHAPTER 2 
This chapter is taken from our first report. It is titled: Cutting Edge: Unique 
T Cells That Recognize Citrullinated Peptides Are a Feature of Protein 
Immunization by Jamie Ireland, Jeremy Herzog and Emil R. Unanue  and was 
published in the Journal of Immunology in volume 177 on pages 1421-1425 in 
2006. It is reprinted with the permission of the Journal of Immunology.  
(Copyright 2006. The American Association of Immunologists, Inc.) 
 It is the first description in the literature of T cells clones that exclusively 
recognize citrullinated epitopes and the ability of APC to citrullinated antigen 
during processing for presentation on MHC II molecules. This project was 
initiated to evaluate presentation of citrullinated peptides. Our first aim was to 
develop a system by which we could detect presentation of citrullinated peptides. 
Since citrullination leads to such a small change in molecular weight (1 atomic 
mass unit), mass spectrometry was not a practical choice for a first general 
evaluation of antigen presenting cells. We chose to use HEL as a model antigen 
because processing and presentation of HEL on I-Ak has been well studied and 
we have access to several potentially useful reagents. The major findings of this 
paper are: 
1- Immunization of B10.BR mice with HEL in CFA gives rise to a T cell 
response that includes T cells that specifically recognize citrullinated 
peptides. This suggests that APC that are priming T cells are presenting 
some level of citrullinated peptides. 
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 2- Two panels of hybridomas were examines in this study to two citrullinated 
variants of immunodominant epitopes of HEL on I-Ak; 48-62cit61 and 114-
129cit125. In Figures 1 and 2 of this paper we demonstrate that the 
reactivity of these hybridomas is specific to citrullinated peptides and there 
is no cross reactivity to unmodified peptides. We further show that the T 
cell contacts are still required for reactivity. 
3- Citrullination of 48-62 leads to little change in binding. However the 
change of 114-129 to 114-129cit125 leads to an increase in binding 
affinity by removing the Arginine at P7 which is a hindering residue. A 
similar increase in binding affinity has also been reported in some 
peptides binding to RA susceptible HLA alleles that contain the shared 
epitope. The results or our binding assays are summarized in Table 1.  
4- Peritoneal macrophages and bone marrow derived dendritic cells present 
citrullinated peptides after processing whole unmodified HEL. Figure 3 
shows 3 hybridomas that recognize 48-62cit 61 respond to presentation of 
HEL. There some small enhancement in the presence of LPS, however 
further studies have shown that this is not specific to presentation of 
citrullinated peptide and is also seen with presentation of the unmodified 
peptide. 
Together these findings demonstrate that citrullinated peptides are presented 
after processing and suggest APC may play role in citrullination of antigen in 
vivo. Furthermore, we establish the utility of our hybridomas as a reagent to 
study presentation of citrullinated peptides. 
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 Abstract 
Abs against citrullinated proteins are present in patients with rheumatoid 
arthritis. In this study, we describe a unique cohort of T cells that selectively 
responded to citrullinated variants of two epitopes of hen egg-white lysozyme, a 
major and a minor one, bound to the MHC molecule, I-Ak. In addition, we show 
that when given an intact, unmodified lysozyme protein, dendritic cells and 
peritoneal macrophages presented citrullinated peptides and stimulated 
modification-specific T cells. Thus, presentation of citrullinated-peptide-MHC 
complex is a feature of immune responses to protein Ags.  
Introduction 
Antibodies to a variety of citrullinated proteins are found in a very high 
number of patients with rheumatoid arthritis (RA)3 and can be used as a highly 
specific clinical index of the disease. Citrullination of arginines is a 
posttranslational change resulting from the action of peptidylarginine deiminases 
(PAD), a family of enzymes found in different cells including neutrophils, 
monocytes, and macrophages (1, 2, 3, 4, 5, 6). The immunological 
consequences of deimination of arginines are therefore of great interest, 
particularly with respect to their possible pathogenetic significance in RA. The 
issue of whether citrullinated proteins may be autoantigenic has been raised, not 
only in RA but also in cases of inflammatory disease of the nervous system 
where citrullination occurs in myelin basic protein (7, 8). Citrullinated proteins 
have been found to be antigenic (9, 10).  
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 Posttranslational changes have been reported in MHC-bound peptides (11, 12). 
We recently called attention to nitration of tyrosine residues (13) and oxidation of 
tryptophans on peptides from the protein, hen egg-white lysozyme (HEL), bound 
to the class II histocompatibility molecule I-Ak (14). These changes took place 
when APCs were activated during immunological reactions including infections. T 
cells highly specific to the changes were generated in vivo, and some escaped 
negative selection in HEL transgenic mice.  
With the findings of citrullinated proteins in RA, we searched for such a 
modification in MHC-bound peptides using approaches akin to those mentioned 
above. Again, using HEL as a model Ag, we show in this study that T cells 
specifically reactive to citrullinated epitopes were among the responding 
repertoire to immunization with an unmodified HEL protein. We also found that 
APC presented modified peptides when provided an intact, unmodified HEL ex 
vivo. Finding T cells specific to citrullinated peptides adds another dimension to 
the reports of Abs in RA.  
Materials and Methods 
Cell culture 
CD4 T cell hybridomas were made by fusing cells obtained from popliteal lymph 
nodes 7 days postimmunization with 10 nmol of HEL in CFA. First, lymphocytes 
were cultured for 1 wk in the presence of 1 µM peptide. The cells were then 
stimulated with fresh peptide and irradiated splenocytes as APC. Three days 
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 later, the cells were fused to BW5147 - -thymoma cells line, as described 
previously (15).  
C3.F6 B lymphoma cells were used as APC for examining the response to the 
various peptides. Peritoneal macrophages were obtained by i.p. injection with 
100 µg of Con A. After 4 days, peritoneal exudate cells (PEC) were harvested. 
Dendritic cells (DC) were derived from bone marrow cultured for 6 days in GM-
CSF containing medium as described previously (16). Hybridoma activation was 
measured by IL-2 secretion as assayed by CTLL proliferation. ELISPOT assays 
were conducted according to the BD Biosciences protocol.  
For limiting dilution cloning, mice were immunized with 10 nmol of HEL in CFA in 
the hind footpads. Seven days later, popliteal lymph nodes were harvested. 
Lymphocytes were plated in round-bottom plates with 5 x 105 irradiated (2000 
rad) splenocytes with 50 U/ml rIL-2 and 5 µM 48–62cit61 peptide. Clonal growth-
positive wells were maintained in these culture conditions.  
Mice and reagents 
B10.BR mice, usually 6- to 12-wk-old, of both sexes were obtained from The 
Jackson Laboratory and maintained in facilities at Washington University. 
B10.BR-Tg(KLK4mHEL)6Ccg mice expressing membrane HEL under the class II 
E  promoter were generated and maintained by our laboratory (15). HEL was 
obtained from Sigma Chemical and purified to eliminate contaminant proteins and 
40 
 
 LPS. Peptides were synthesized using Fmoc techniques. LPS (Sigma-Aldrich) 
was used at a final concentration of 1 µg/ml.  
RT-PCR 
RNA was isolated using the RNeasy kit (Qiagen) according to the manufacturer’s 
instructions. The RNA was treated with DNA-free (Ambion), then reverse-
transcribed using Superscript First-Strand Synthesis (Invitrogen Life 
Technologies), and amplified using the following primer sequences: PAD2, 
TACAGATTCCCGTACACGTTGCGT and AACTGGCCAGAGAATTGAGGACCA 
with an expected amplicon of 245 bp; and PAD4, 
CCAAGAAAGCCAAGTGCAAGCTGA and TTCCCGATGAGAATTCTGCCCAGT 
with an expected amplicon of 316 bp.  
Relative binding affinity 
Peptide-binding affinity for I-Ak was measured as described previously (17), using 
baculovirus-purified I-Ak molecules. Results indicate the concentration of 
unlabeled peptide that inhibited by half the binding of an 125I-labeled peptide 
standard.  
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 Results  
Immunization with HEL gives rise to T cells that are specific to citrullinated 
epitopes 
Mice were immunized with HEL in CFA, and 1 wk later the draining lymph 
node cells were isolated and screened for CD4 T cells to citrullinated HEL 
epitopes. After a 7-day culture in the presence of citrulline (either HEL 48–62cit61 
or HEL 114–129cit125) (Table I), followed by a 3-day stimulation with irradiated 
splenocytes, the cells were fused to create T cell hybridomas. In a different 
approach, the lymph node cells of the mice immunized with HEL were placed in 
an ELISPOT assay against the modified peptides, or were cloned by limiting 
dilution.  
  Peptide 48–62 represents the major chemically dominant segment of HEL 
selected from its processing (18). This family of peptides centers on the nine-
residue core from 52 to 60. Arginine, underlined, is the tenth residue on this 
peptide: DYGILQINSRW. The crystal structure of the 48–62 peptide bound to I-Ak 
showed that the P10 arginine and the P11 tryptophan were solvent exposed (19). 
As expected, changing the arginine 61 to citrulline did not change the binding of 
the 48–62 peptide to purified I-Ak molecule (Table I).  
 Several hybridomas were found that responded to 48–62 with a 
citrullinated P10, and not to the wild-type arginine residue. Three representative T 
cells are shown in Fig. 1A, labeled Pepe, Granny, and Marvin, and each 
responded with varying degrees of sensitivity to 48–62 but only with a citrulline in 
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 place of the arginine at P10. These hybridomas did not secrete IL-2 in response 
to stimulation with wild-type peptide. All of the citrulline-specific hybridomas 
showed an absolute dependence on the presence of the tryptophan at P11, that 
is, responded to 48–62cit61 but not 48–61cit61. This finding is not surprising as 
the screening process selected for a population of T cells whose receptors 
recognized C-terminal residues. About half of the T cells that responded to the 
48–62 segment of HEL also required the presence of Trp62 (20, 21).  
It is known that most of the T cells that interact with the 52–60 core 
segment interact with three TCR contact residues, Tyr53, Leu56, and Asn59 (19, 
21, 22). Such was the case for the T cells that recognized cit61 (Fig. 1B). None 
recognized the alanine substitutions for Tyr53 or Asn59. Additionally, the 
response was severely hindered when leucine at the P5 position, a centrally 
positioned TCR contact, was replaced by an alanine. Whether the TCR directly 
interacted with the cit61 and Trp62, or the latter imparted a conformational change 
of the three TCR contact residues of the core segments is not known.  
To further define the specificity of the hybridomas reactive with 48–
62cit61, we assessed the effects of several amino acid substitutions at the Arg61 
residue (Table II). Replacement of the Arg61 with alanine or glycine resulted in a 
markedly diminished response. The substitution of glutamine, an amino acid with 
structural similarities to citrulline, induced a similar or smaller response among 
the various T cell hybridomas. (Fig. 1A and Table II). In contrast, substitution at 
P10 with lysine completely abrogated the response in data not shown. T cell 
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 hybridomas that recognize unmodified 48–62 were tested for reactivity to the 
modified peptides: we found no difference in the responses to stimulation with the 
various substitutions.  
  ELISPOT analysis of spleen cells from mice immunized with HEL indicated 
that frequency of T cells reactive with 48–62cit61 is 1:36,000. The ELISPOT, 
however, did not distinguish those T cells that exclusively reacted with the 
citrullinated peptides. The frequency of T cells responding to 48–62 was 
1:25,000. We therefore conducted cloning of primary T cells from HEL-
immunized mice by limiting dilution. Each clone was tested against 48–62 and 
48–62cit61. Analysis of 23 primary T cell clones showed that 8, or 35%, reacted 
only to 48–62cit61, whereas the other 15 responded to both 48–62cit61 and 48–
62.  
Peptide 114–129 binds weakly to I-Ak molecules, although it induces a 
relatively strong T cell response (23). The binding core in 114–129 is from 
residues 119–127: DVQAWIRGC. Arginine is at P7 in the peptide and is known 
to be a negative or hindering residue. Peptide 114–129cit125 bound with an IC50 
of 1 µM, whereas the unmodified peptide bound at 3.8 µM (Table I). These 
findings are in agreement with a recent report on the binding of a citrullinated 
peptide to HLA DRB1*0401 (24).  
Immunization with HEL and selection for T cells that recognized a citrulline 
for the Arg125 resulted in T cells that specifically recognized the modification. 
Two representative T cells specific for the 114–129 peptide with citrulline at 
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 residue 125, C68 and Everardo, are shown in Fig. 2. Unlike the hybridomas that 
recognize 48–62cit61, these did not react with peptides in which the arginine at 
125 was replaced with glutamine. Similarly, hybridomas that recognized the 114–
129 epitope did not recognize the citrullinated peptide (Table II). Two ELISPOT 
assays were done. The number of 114–129-reactive T cells after HEL 
immunizations were 1:24,539 and 1:36,000. The numbers of 114–129cit125-
reactive T cells were much less: 1:70,000 and 1:142,857. Collectively, these data 
indicated that citrullinated peptides were presented in vivo, from HEL processing, 
and elicited specific T cell responses.  
  
Primary APC present modified peptides when given whole HEL 
 
We tested the abilities of different APC to present the modified peptides 
when cultured with HEL. To this end, we examined bone marrow-derived DCs 
(BMDC), adherent PECs, or the C3.F6 B lymphoma line (Fig. 1A), as APC. C3.F6 
pulsed with whole HEL did not stimulate the hybridomas that were specific to 48–
62 cit61. The hybridomas specific for 48–62cit61 responded to whole HEL when 
presented by BMDC (Fig. 3A) or PEC (Fig. 3B). The response was increased 
after addition of LPS to the cultures: with Marvin the response was only detected 
after LPS stimulation. In addition, DC (CD11b–, CD11c+) and macrophages 
(CD11b+, CD11c–) isolated from B10.BR spleens pulsed with HEL presented 48–
62cit61.  
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 In data not shown, less sensitive hybridomas responded weakly or not at 
all, suggesting that the levels of 48–62cit61 may be limiting. In support of this 
idea, the 114–129cit125-specific hybridomas, C68 and Everardo, did not respond 
to HEL presented by BMDC or PEC. Both of these hybridomas are much less 
sensitive. The levels of the 114–129 epitope of HEL presented on I-Ak are low 
relative to the levels presented by the 48–62 family. Lastly, in data not shown we 
found that BMDC and PEC from lysozyme transgenic mice stimulated the 48–
62cit61 hybridomas. The B lymphoma line C3.F6 did not present to either set of T 
hybridomas (Figs. 1 and 2). The conversion of arginine to citrulline requires the 
activity of PAD enzymes, which are cytosolic or nuclear and are active only at 
high calcium concentrations, 10–5 M (4). There have been several reports 
indicating that monocytes express PAD enzymes (25, 26, 27, 28), and in this 
study we indicate that both BMDC and peritoneal macrophages expressed PAD2 
and PAD4 by RT-PCR. C3.F6 expressed PAD2 but not PAD4 (Fig. 3C).  
Discussion 
  The surprising observation made in this study is the presence of T cells to 
citrullinated peptides upon immunization with the highly immunogenic HEL 
protein. HEL was given in CFA, which induces a strong inflammatory response. 
In a previous study, we found that, in the draining lymph node, 1% of 
macrophages and DC contained the HEL following similar conditions of 
immunization as used here (29). Actually, by ELISPOT, the number of T cells 
reactive with the citrullinated peptides was relatively high. We conclude that 
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 strong immunization measures can drive the process in APC that leads to 
citrullination of protein segments that are processed into peptide-MHC 
complexes. Now that we recognize that such T cells exist, we are actively 
searching for them in different specific tissue autoimmunities and inflammatory 
conditions as well as outlining the mechanisms of citrullination of Ag during 
presentation by APC.  
The steps involved in citrullination of Ag require analysis, taking into 
consideration the properties of the PAD enzymes. The mechanism by which 
presentation of the modified epitopes occurs is puzzling considering the high 
level of calcium required and the localization of the enzymes in the cell. A high 
calcium level could take place during apoptosis, although we have not discerned 
an obvious apoptotic response in our cultures. The lack of presentation by C3.F6 
suggests that PAD4 may be the critical enzyme, but this conclusion needs to be 
substantiated in experiments where this enzyme is removed from DC or 
macrophages. Such experiments are in progress.  
Having identified specific T cells to citrullinated proteins as part of the 
response to immunization now begs the question of their immunopathologic role. 
What is their meaning in the context of the findings in RA? Because citrullination 
of proteins in the joint is such a striking feature, will T cells to the modified 
epitopes be enriched there? If such T cells develop in inflamed joints against 
protein components, will they be pathogenic? The issue of whether these 
responses are involved in disease pathogenesis or a byproduct of a more general 
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 immunological reaction must be clarified before steps to target deimination as a 
treatment are taken. 
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 Table 1. Peptide binding results 
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 Figure 1.  
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 Figure 1. 
 T cell hybridomas are reactive to the 48–62cit61 peptide. A, Hybridomas were 
cocultured with C3.F6 as APC and tested with 1.5 log dilutions of 48–62 
unmodified or with citrulline or glutamine replacements at P10 or whole HEL. B, 
The response of the hybridomas to 48–62 cit61 with alanine substitutions at TCR 
contact positions. 
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 Figure 2.  
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 Figure 2.  
C68 and Everardo are reactive to citrullinated 114–129. Hybridomas were 
cocultured with C3.F6 as APC. HEL or peptide was added to the cultures in 1.5 
log dilutions, and IL-2 secretion was assayed by proliferation of CTLL cells. 
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 Figure 3. 
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 Figure 3. 
 APC present modified peptides from HEL. BMDC (A) or PEC (B) were cultured 
overnight with dilutions of HEL. The cells were washed and cocultured with the 
hybridomas, and IL-2 secretion was assayed. C, Expression of PAD 2 and PAD 4 
in APC used in this study. Total RNA was isolated from cells, reverse-
transcribed, and amplified using internal primers to semiquantitatively detect 
mRNA levels. 
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 CHAPTER 3 
Presentation of citrullinated peptides by class II histocompatibility molecules is 
associated with autophagy. 
This chapter consists of our second report as we prepare to submit for 
publication. In this chapter, we demonstrate a role for autophagy in citrullination 
of antigen by APC. To avoid redundancy, we omit the introduction as the material 
has been covered in chapter one of this thesis. 
 
Presentation of citrullinated peptides by class II histocompatibility molecules is 
associated with autophagy. 
 
Presentation of citrullinated peptides by class II histocompatibility molecules is 
associated with autophagy. 
 
Abstract 
Autoimmune responses to citrullinated proteins have been associated with 
rheumatoid arthritis; however, little is known of the mechanism by which 
tolerance to citrullinated proteins is established or the biology of citrullination by 
cells of the immune system. Using T cell hybridomas that recognize citrullinated 
peptides from hen egg-white lysozyme (HEL) we have shown antigen presenting 
cells (APC) present citrullinated peptides after processing whole unmodified 
protein. APC isolated from the draining lymph node of mice immunized with HEL 
in complete Freund's adjuvant presented citrullinated peptides. Examination of 
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 APC from HEL transgenic mice revealed that splenic dendritic cells, 
macrophages and thymic dendritic cells presented citrullinated peptides 
constitutively. Treatment of APC with 3-Methyladenine (3MA) blocked 
presentation of citrullinated peptides but presentation of unmodified peptides was 
not affected. Presentation of citrullinated peptides was not detected on splenic B 
cells or B lymphoma cells under normal culture conditions. B cell receptor 
engagement has been shown to induce autophagy in primary B cells. We 
examined presentation of HEL by B cells from anti-HEL transgenic mice, in which 
all B cell receptors bind HEL, and found that, in contrast to B cells from B10.BR 
mice, they presented citrullinated peptides. B cells from mHEL mice presented 
citrullinated peptides after BCR engagement with anti-IgM or anti-IgG antibodies. 
Induced presentation of citrullinated peptides was blocked by 3MA. We find that 
C3.F6.mHEL B lymphoma cells presented citrullinated peptides after serum 
starvation and this was also blocked by 3MA treatment. Higher levels of citrulline 
in naturally processed peptides from these cells were detected biochemically 
after culture in serum starved conditions. Furthermore, C3.F6.mHEL cells that 
stably express shRNA targeting Atg5, a protein essential for autophagy, did not 
present citrullinated peptides after serum starvation. Our findings demonstrate a 
role for autophagy in citrullination of antigen during processing by antigen 
presenting cells and a link between antibodies to immunoglobulin and 
presentation of citrullinated peptides. 
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Results 
 
Primary APC present citrullinated peptides in vivo. 
 
We generated a panel of hybridomas that exclusively recognize 
citrullinated peptides by fusing T cells isolated from the draining lymph nodes of 
mice immunized with whole unmodified HEL in CFA. The responses of these 
cells provide a useful reagent with which to detect the presentation of citrullinated 
peptides. In the series of experiments described here we compare the response 
of Granny, which exclusively recognizes the HEL peptide, 48-62cit61 on I-Ak [1], 
to 3A9 which recognizes the 48-62 peptide (DGSTDYGILQINSRW). 
           
In order to determine if presentation of citrullinated peptides by class II-
MHC molecules occurs in vivo, we examined APC from mHEL mice, which 
express HEL linked to the transmembrane region of Ld under the I-E promoter 
and therefore in every MHC class II expressing cell. Presentation of HEL 48-62 
by APC in these mice is strong, found to be 3,400–20,000 pMHC complexes per 
cell [2]. We isolated CD11c+ cells from the thymus and spleen of these mice. In 
addition to eliciting a robust response to the dominant HEL peptide 48-62 (using 
as indicator cell the CD4 T cell hybridoma 3A9) (Fig. 1b&d), the APC also 
presented 48-62cit61 (using Granny as the indicator T cell) (Fig. 1a&c). In 
contrast, splenic CD19+ cells did not elicit a response from the 48-62cit61 
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 reactive hybridoma though the response of 3A9 was strong (Fig. 1e&f). This last 
finding is in concordance with our previously published results demonstrating that 
a B cell lymphoma did not present citrullinated peptides after processing HEL [1]. 
 
Since T cells that recognize citrullinated peptides were first isolated from 
lymph nodes of mice after immunization with HEL in adjuvants, we verified the 
presentation of citrullinated peptides by APC in the draining lymph nodes. 
B10.BR mice were immunized with 10nmol HEL in adjuvant (Complete Freund’s) 
and their APC from draining lymph nodes were isolated 24 hours later and then 
examined for their presentation to the indicator T cells. These APC, in addition to 
presenting HEL 48-62 (Fig. 1 g&h) presented HEL 48-62cit61.  
 
Serum starvation induces presentation of citrullinated peptides by B 
lymphoma cells. 
 
C3.F6.mHEL is a B lymphoma line that expresses HEL with a trans-
membrane linker and constitutively presents high levels of HEL peptides on I-Ak 
molecules [3]. Such a line did not present the citrullinated HEL peptides and was 
used here to examine the reasons for such a negative response and the 
conditions that may induce it. Attempts to induce citrullination by activating the 
C3.F6.mHEL line with endotoxin, tumor necrosis factor or interferon-gamma 
failed. However there was a striking response by Granny after the cells were 
serum starved by reducing the amount of fetal calf serum (FCS) from 5% to 1% 
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 or without FCS for a limited period of time (Fig. 2a). We did not observe a 
significant increase in dead cells by trypan blue exclusion in the cultures that had 
been serum starved. A similar positive response was found after irradiation of the 
cells by ultraviolet light.  
 
This response led us to question whether the B cell line was undergoing 
autophagy as a result of the stress signals. The serum starved cells were treated 
with 3-methyladenine (3MA), a class III PI3 kinase inhibitor during the period of 
serum starvation. 3MA was previously shown to inhibit autophagy [4, 5], although 
effects on other components of intracellular protein processing and or catabolism 
cannot be ruled out. The response by Granny to the serum starved cell line was 
completely blocked by treatment with 3MA (Fig. 2a). In contrast to the striking 
effect by 3MA on the presentation of the citrullinated peptide, the response to the 
unmodified 48-62 peptide by 3A9 was not affected at all (Fig. 2c). There was no 
significant difference in presentation of synthetic peptide indicating that the levels 
of MHC molecules were not altered by serum removal or 3MA treatment (Fig. 
2b). 
 
We confirmed that the culture of C3.F6.mHEL without FCS induced an 
autophagy response by finding an increase in the levels of LC3 II which was 
reduced by 3MA treatment (Fig. 2d). Thus the 3MA effect was highly selective for 
presentation to the cell line that recognized the citrullinated derivative of HEL. 
The specific effect of 3MA only on presentation of the citrullinated epitope and 
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 not on the unmodified one strongly pointed to autophagy as participating in the 
presentation of citrullinated peptides in these APC.  
 
Presentation of citrullined peptide by primary APC is inhibited by 3-
Methyladenine. 
 
In culture, PEC and BMDC pulsed with HEL presented the 48-62Cit 61 
epitope. We next addressed the possibility that the presentation of citrullinated 
peptides by PEC and DC would also be a target of 3MA, perhaps dependent on 
constitutive autophagy. Several reports indicated that APC constitutively 
underwent autophagy and that this process contributed to the repertoire of 
peptides presented on MHC class II molecules [6-12]. Both PEC and BMDC 
were pulsed with 3MA and HEL overnight, then assessed for their presentation of 
peptides to the two T cell hybridomas. The addition of 3MA profoundly inhibited 
the presentation of citrullinated peptides to Granny (Fig. 3 a&c). The inhibition 
was dependent on the dose of 3MA (Fig. 3 b&d). In contrast, presentation of HEL 
peptides to 3A9 was not effected at all over a range of concentration. 
Additionally, presentation of synthetic peptide was not changed by 3MA 
treatment. Thus the 3MA inhibition of HEL presentation by PEC and BMDC, also 
was highly selective only affecting that of the 48-62cit61 epitope. 3MA was not 
having a non-specific inhibition of HEL processing. 
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 Knockdown of expression of Atg 5 inhibits presentation after serum 
starvation of B lymphoma cells 
 
Although 3MA is generally accepted to inhibit the autophagy pathway, 
there have been reports that it may have some pleiotropic effects. In neuronal 
cells 3MA was shown to inhibit apoptosis and mitochondrial permeability 
transition [13, 14]. In colon cancer cells there was a minor increase in the 
mitochondrial protein, oligomycin sensitivity conferral protein, only in amino acid 
deprived cells [15]. In isolated hepatocytes 3MA was shown to induce glycogen 
breakdown through an increase in cyclic AMP and decreased the ability of the 
cells to accumulate chloroquine [16]. In addition it has been observed that in 
some situations, 3MA may actually induce autophagy [17].  Our data show that 
treatment of APC with 3MA had no effect on presentation of 48-62 to 3A9, even 
at low antigen doses; however, we wanted to completely rule out the possibility 
that the effect we observed with 3MA could be due to an effect independent of 
autophagy. Thus, we assessed whether an alternative method of inhibition of 
autophagy would recapitulate our findings. To this end we designed shRNA 
constructs to target expression of Atg5, a protein essential for autophagy, and 
cloned them into a lentiviral delivery system in which infected cells express green 
fluorescent protein (GFP) and can be purified by flow cytometry. C3.F6.mHEL 
cells were infected and the GFP expressing  cells were sorted and examined. As 
a negative control, cells were infected with virus containing shRNA that targets 
Luciferase expression. The shRNA system effectively reduced Atg5 expression 
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 by western blot (Fig. 4e). rtPCR indicated a 72% decrease in Atg5 message 
relative to Luciferase knockdown controls. The cells exhibited reduced levels of 
LC3 II conversion.  
We cultured these cells in media with various amounts of FCS for 3 hours 
before changing to DMEM with 5% FCS and adding T cell hybridomas. In the 
control cells in which Luciferase expression was targeted, there was strong 
presentation of citrullinated peptides only upon serum starvation. The same cells 
cultured in 5% FCS did not present (Fig. 4a). Inhibition of expression of Atg5 
affected presentation of citrullinated peptides in serum-starved cells (Fig. 4b). In 
contrast, neither serum starvation nor expression of Atg5 had any bearing on 
presentation of the unmodified epitope, HEL 48-62 (Fig.4 c&d). This result is 
consistent with our data demonstrating 3MA inhibition of presentation of 
citrullinated peptides and supports the conclusion that autophagy played a role in 
citrullination of antigen by APC.  
 
Primary B cells present citrullinated peptides after BCR engagement. 
 
It has been shown that B cell receptor (BCR) engagement induces 
autophagy in primary B cells [18, 19]. We purified B cells from anti-HEL B cell 
transgenic mice and cultured them overnight with HEL +/- 3MA. We found that, in 
contrast to B cells from B10.BR mice, they do elicit a response from Granny after 
processing whole unmodified HEL (Fig. 5a). 3MA did not inhibit presentation of 
HEL 48-62cit61 when it was removed from the culture before the addition of T 
69 
 
 hybridomas (Fig 5b); however, we observed inhibition of presentation of 
citrullinated peptides after processing HEL in these B cells when they are fixed 
immediately after 3MA removal (Fig 5c). The effect of 3MA treatment is rapidly 
reversible [4] and we speculate that the signals that drive autophagy induced by 
antigen binding are still in effect when the cells are washed for the addition of T 
cells. The response of 3A9 to presentation of HEL by transgenic B cells is 
strongly enhanced when compared to B10.BR as expected as BCR mediated 
uptake is known to lead to highly efficient presentation of antigen [20].  
 
To determine if BCR mediated uptake for presentation is required for 
trafficking of antigen to a particular compartment for citrullination or if BCR 
engagement induced autophagy is sufficient for presentation of citrullinated 
peptides we examined B cells from mHEL mice. Treatment of these B cells with 
anti-IgM induced presentation of HEL 48-62cit61 (Fig. 5d). We observed identical 
results with F(ab')2 fragments. These results are not due to endotoxin 
contamination in the antibody as LPS treatment of these cells does not induce 
presentation of citrullinated peptides. Interestingly, treatment of B cells with anti-
IgG also induced presentation of citrullinated peptides. Induced presentation of 
citrullinated peptides by both anti-IgM and anti-IgG was inhibited by treatment 
with 3MA, indicating that autophagy is required. In support of this conclusion, we 
find that LC3 conversion is induced by treatment with anti-IgM and anti-IgG and 
is inhibited by 3MA treatment (Fig. 5f). To examine the intracellular events that 
were occurring after BCR engagement, we examined B cells from GFP-LC3 
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 mice. As expected, treatment with anti-IgM lead to capping and internalization of 
surface IgM. After treatment with anti-IgM, LC3 positive vesicles were observed 
which colocalized with MHC II vesicles and internalized IgM (Fig. 5g), thereby 
demonstrating an association of autophagic vesicles with BCR mediated uptake 
and processing for presentation on MHC II. 
  
 
PAD2 and PAD4 levels are not affected by serum starvation or treatment 
with 3MA.  
 
PAD activity has several levels of regulation; transcriptional, post-
transcriptional [21], post-translational [22], and though a requirement for Ca++ 
[23].  In our own experiments, we found that over-expression of PAD4 in B 
lymphoma cells did not lead to presentation of citrullinated peptides however; we 
raised the question of whether treatment with 3MA, serum starvation, or 
decrease in Atg5 expression was modulating presentation of citrullinated 
peptides by influencing PAD expression levels. Figure 7 shows expression of 
PAD2 and PAD4 mRNA relative to untreated cells. There was no difference in 
PAD expression levels as determined by rtPCR. The data shown are normalized 
to beta actin levels and are similar to results we found when we normalized to 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 18s rRNA, and 
Hypoxanthine-guanine phosphoribosyl transferase (HPRT). We conclude that the 
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 effect of serum starvation and 3MA treatment on autophagy was not influencing 
PAD expression in these cells.  
 
Biochemical evaluation of naturally processed peptides demonstrates the 
positive effect of serum starvation. 
 
A biochemical method that has been used to detect citrulline in biological 
samples targets its unique ureido group and can be used to quantify citrulline by 
a colorimetric assay [24, 25]. This method is based on the reaction of diacetyl 
monoxime (DAMO) with urea under acidic conditions and a second reaction with 
antipyrine. The product of this reaction has been recently identified to be 3-butyl-
4-[(2,3-dihydro-1,5-dimethyl-3-oxo-2phenyl-1H-pyrazol-4-yl)methyl]-5-1H-
imidazol-2(3H)-one [26]. We cultured C3.F6.mHEL in DMEM supplemented with 
5% or 1% serum and, after lysis, isolated I-Ak peptide complexes. The peptides 
were separated from the Class II molecules and chemically modified to label 
citrullinated peptides. Table 1 summarizes the results of these experiments. 
Though there is some variability between experiments, the amount of citrulline 
detected in peptides from cells incubated in 1% FCS was higher than that from 
cells cultured in 5% serum. These data support our findings with citrullinated 
peptide reactive T cell hybridomas and our conclusion that serum starvation 
leads to an increase in presentation of citrullinated peptides. 
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Discussion  
 
Autophagy is a ubiquitous catabolic process by which cytosolic 
components are shuttled in to vesicular compartments for degradation in 
lysosomes. This process has been conserved through evolution and is involved 
in the homeostatic degradation of cytosolic proteins and turnover of senescent 
organelles [27-35].  
 
Studies evaluating naturally processed peptides from MHC II molecules 
have revealed that peptides derived from cytosolic proteins are presented at 
significant levels [6, 7, 36-40]. There have been several recent reports describing 
the contribution of the autophagic pathway to MHC II peptides [8, 10-12].  
 
We found that APC, including thymic DC, from HEL transgenic mice 
present citrullinated peptides in vivo which was inhibited by 3MA. Inhibition of 
autophagy through 3MA has been shown to be relatively specific with only a few 
reports citing other effects [13-16]. We show here that 3MA has no effect on 
presentation of 48-62 to 3A9, even at low antigen doses. 3MA does not inhibit 
processing of HEL in general and the effect is specific to citrullination of antigen.  
Primary B cells from B10.BR mice did not present HEL 48-62cit61 after 
processing whole HEL under normal conditions. The poor presentation by B cells 
and B lymphoma cells could be attributed to an absence or poor expression of 
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 the PAD enzymes which convert arginine to citrulline. PAD2 and PAD4 are 
expressed in APC. Based on a study examining expression of PAD in leucocytes 
[21] and our own published results [1], PAD4 is expressed at lower levels in B 
cells and C3.F6.mHEL. We over expressed PAD4 in C3.F6 and found no 
difference in presentation of citrullinated peptides. In addition, we observed that 
treatment with 3MA, serum starvation, and inhibition of Atg 5 expression had no 
effect on PAD2 and PAD4 expression levels. These data indicate that the limiting 
factor in citrullination of antigen by APC is not PAD expression levels alone.  
 
Primary B cells presented citrullinated peptides derived from HEL taken up 
via the BCR. In addition, we found that engagement of the BCR with antibody 
lead to presentation of HEL 48-62cit61 in cells that express membrane linked 
HEL. This data raises the question of how rheumatoid factor may factor in to the 
generation of autoimmune responses to citrullinated self-proteins.  It is possible 
that induced presentation of citrullinated self-proteins, especially in the context of 
MHC II molecules that effectively bind these peptides, as has been shown with 
shared epitope containing alleles, could be one of the precipitating events that 
lead to the initiation of an autoimmune process.  
 
The exact mechanism by which autophagy contributes to citrullination of 
antigen is unknown. We speculate that it acts by allowing PAD enzymes to gain 
access to antigen loading compartments. In addition, autophagic degradation of 
senescent organelles may act as a source of Ca++ to allow PAD activity. 
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PAD2 has been reported in the literature to be localized to the cytosol and 
PAD4 in the cytosol or nucleus [41-43]. A report by Mastronardi et al. showing 
translocation of PAD4 from the cytosol to a vesicular compartment and then to 
the nucleus of oligodendroglial cells after treatment with tumor necrosis factor 
prompted us to determine if we could detect PAD4 in LC3+ vesicles by confocal 
microscopy [44]. As expected, we found that PAD4 primarily localized to the 
nucleus. We observed some cytosolic staining but no obvious staining in LC3+ or 
Class II + vesicles. Since PAD proteins are enzymes, small amounts can 
potentially produce significant observable activity. In our panel of hybridomas that 
we generated we found that only the most sensitive hybridomas to 48-62cit61 
responded to presentation of whole HEL by APC [1]. We would not expect to see 
high levels of PAD enzymes in antigen loading compartments based on the 
levels of citrullination we observe by APC.  
 
What is the reason behind citrullination of antigen by APC? There are 
several possible teleological explanations for this. It is known that citrullination 
alters intramolecular interactions and can lead to increased accessibility to 
proteolysis [45, 46]. This may be a mechanism to assist in protein degradation 
within lysosomes. In addition, the change from arginine to citrulline has been 
shown in some cases to alter peptide MHC affinity and the conformation of the 
peptide in the binding groove [47-49] and may have a role in expanding the 
repertoire of peptides that can be presented on a particular MHC haplotype. 
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 Finally, constitutive, low level presentation of citrullinated self-peptides may play 
a role in the establishment of tolerance. Citrullination plays a role in several 
normal biological processes and citrullinated proteins are present in healthy 
individuals. 
 
Though it is likely a gross oversimplification, the notion that citrullination of 
self-antigen represents a mechanism by which tolerance can be breached is 
attractive because it provides a clear explanation for a potential cause of RA. The 
idea that adaptive responses are occurring to proteins that have been 
citrullinated and then made available to APC for processing and presentation has 
been the basis of much of the research on the role of citrullinated epitopes in 
disease. We present here evidence that suggests that APC could be a source of 
citrullinated antigen and that the local environment may potentially contribute to 
enhanced presentation of citrullinated epitopes. This is an additional factor that 
one should consider when thinking about citrulline and autoimmunity. 
 
In summary, using T cell hybridomas that exclusively recognize 
citrullinated peptides we have shown that induction of autophagy can induce 
presentation of citrullinated peptides while inhibition of autophagy, both 
chemically using 3MA and by inhibiting Atg5 expression blocks presentation of 
citrullinated peptides. B cells that have taken up antigen via the BCR present 
citrullinated peptides. Interestingly, BCR engagement by anti-immunoglobulin 
antibody induces presentation of citrullinated peptides by B cells. Biochemical 
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 analysis of naturally processed peptides from cells grown in serum starved 
conditions confirms that there is an increase in citrulline levels. We conclude that 
autophagy is associated with citrullination of antigen by APC. 
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Figure 1 Antigen presenting cells present citrullinated peptides in vivo. 
CD11c+ cells isolated from thymi (a,b) or spleen (c,d) and CD19 + cells isolated 
from spleens (e,f) of mHEL mice using magnetic bead purification. B10.Br mice 
were immunized in the hind footpad with 10 nmol HEL in CFA. After 24 hours, 
the popliteal lymph nodes were collected. CD11c+ and CD11b+ cells were 
purified by magnetic bead purification and used as APC (g,h). Cells were 
cultured with either Granny (a,c,e,g) or 3A9 (b,e,f,h) overnight. Cell were co-
cultured overnight and supernatants were collected. IL-2 was measured by CTLL 
proliferation assay. 
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Figure 2. C3.F6.mHEL present citrullinated peptides after serum starvation. 
C3.F6.mHEL were cultured in DMEM supplemented with 5% fetal calf serum or no 
serum  overnight.  The culture medium was then changed to DMEM with 10 % fetal calf 
serum and T cell hybridomas were added. Synthetic peptide [3μM] was added as a 
positive control (b). After overnight incubation the culture supernatants were collected 
and IL-2 levels were measured by CTLL proliferation assay. D-C3.F6.mHEL were 
cultured in DMEM supplemented with either 10 % serum or no serum and treated with 
chloroquine for the last hour of culture. Levels of LC3 II  and actin were measured by 
western blot. 
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Figure 3 
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Figure 3. Treatment with 3-Methyladenine inhibits presentation of 
citrullinated peptides. 
BMDC (A and B) or PEC (C and D) were cultured overnight with  3-
Methyladenine [10mM] and dilutions of HEL or peptide in 96 well plates(A and C) 
or HEL or peptide and dilutions of 3-Methyladenine (B and D). They were 
washed and cultured overnight with T cell hybridomas that recognize HEL 48-62 
presented by I-Ak. After incubation overnight, the culture supernatant was 
collected and IL-2 levels were measured by CTLL proliferation assay.  
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Figure 4. Targeted knockdown of Atg5 expression has an inhibitory effect 
on citrullination of antigen. 
C3.F6.mHEL cells expressing either shRNA targeting Lucifierase (Luc) 
expression (a and c) or Atg5 expression (b and d) were cultured in DMEM 
supplemented with 5% FCS, 1% FCS, or no FCS for 2 hours. The culture 
medium was replaced with DMEM supplemented with 5% FCS and T cell 
hybridomas were added and IL-2 in the culture supernatant was measured by 
CTLL proliferation assay. e- Atg5 and LC3 II levels in Luciferase knockdown 
control cells and Atg5 knockdown cells were assessed by western blot.  
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Figure 5. B cells present citrullinated peptides after BCR mediated uptake 
or treatment with anti-IgM or anti-IgG.  
(a)Splenic CD19+ cells from B10.BR or anti-HEL mice were cultured with HEL 
and either Granny or 3A9. (b) B cells from anti-HEL mice were cultured with HEL 
+/- 3MA overnight then washed before Granny was added to the culture. (c) B 
cells treated as in b but fixed before addition of Granny. (d) Splenic CD19+ cells 
from mHEL mice were cultured with dilutions of anti-IgM or anti-IgG and Granny. 
IL-2 production was measured by CTLL assay. (e) LC3 conversion was assessed 
by Western blot in B cells treated with anti-IgM or anti-IgG +/- 3MA. (f) Splenic B 
cells from GFP.LC3 mice were labeled with anti-IgM on ice and fixed at 0h and 
1h after transfer to 37°.  
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 Figure 6 
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Figure 6. Relative Expression of PAD2 and PAD 4 after treatment. 
PAD2 and PAD4 expression was measured in cells after treatment with 3MA, 
serum starvation (SS) or serum starvation and 3MA treatment. Delta delta CT 
values are relative to untreated cells and normalized to actin. 
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Experiment  Culture 
nmol  
cit/10e9 cells Fold increase 
1 1% serum 5.05 2.46 
  5% serum 2.06   
        
2 1% serum 2.62 8.73 
  5% serum 0.30   
        
3 1% serum 18.19 13.50 
  5% serum 1.35   
        
4 1% serum 2.37 2.25 
  5% serum 1.05   
 
Table 1. Quantitation of citrulline in naturally processed peptides. 
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 Chapter 4 
Concluding Remarks and Future Directions 
Summary  
 The aim of this project was to evaluate citrullination by APC. The system 
we developed to detect presentation of citrullinated peptides is a specific and 
sensitive response by T cell hybridomas. We demonstrate here that APC have 
an intrinsic ability to citrullinate antigen both constitutively, as in the case of 
dendritic cells and macrophages, and in response to certain conditions, as in the 
case of B cells.  
 Our interest in citrullination in the context of antigen processing and 
presentation stemmed from studies that suggest that an adaptive response to 
citrullinated self-epitopes may be involved in autoimmunity. A major obstacle in 
studying citrulline in naturally processed peptides is that of detection. This project 
began with the question- Can we detect an adaptive immune response to 
citrullinated epitopes in our model? A biological assay is relatively reliable and 
practical when compared to alternative methods by which to detect presentation 
of citrullinated peptides.  
The 3 main findings of this project are the following- 
1- T cells that recognize citrullinated peptides are among those responding 
after protein immunization. We fused T cells taken from several lymph 
nodes of immunized mice and generated hybridomas that exclusively 
respond to presentation of citrullinated peptides.  
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 The specificity of these hybridomas to the citrullinated peptides allowed us 
to detect presentation of citrullinated peptides.  
2- APC citrullinated antigen while processing for presentation. The T cells we 
fused to generate our panel of hybridomas had been primed in vivo after 
protein immunization- the citrullinated peptide had been presented in vivo. 
This conclusion was borne out when we examined APC isolated from the 
draining lymph node of immunized mice. 
Dendritic cells and macrophages present citrullinated peptides 
constitutively, while B cells do not present citrullinated peptides under 
normal conditions.  
3- Autophagy plays a role in citrullination of antigen by APC. 3MA inhibits 
presentation of citrullinated peptides. Serum starvation induces 
presentation of citrullinated peptides. Atg5 knockdown inhibits serum 
starvation induced presentation of citrullinated peptides. Induction of 
autophagy in primary B cells through BCR engagement allows 
presentation of citrullinated peptides. 
This body of work has brought to light the role of APC in citrullination and 
raises several questions for future studies to address. The system that we have 
developed has proven to be a useful method by which citrullination by APC can 
be detected.  
T cells that can exclusively recognize citrullinated peptides are among 
those responding to protein immunization.  
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 Citrullination leads to a minor change in molecular weight- only 1 amu. 
However, the loss of positive charge leads to significantly altered interactions 
with adjacent proteins. In the context of antigen presentation, this change has the 
potential to alter peptide binding affinity or T cell reactivity. In addition to our 
findings, several studies have addressed this effect in various systems.  
In examining subtypes of the human HLA B allele, B*2705 and B*2709, 
which present a peptide from protein vasoactive intestinal peptide type 1 receptor 
in drastically different conformations, crystal structure revealed that the 
citrullinated peptide was similarly presented in different conformations by B*2705 
and B*2709. However, the conformation of the citrullinated peptide was 
completely different from the unmodified peptide. They further determined that 
cytotoxic T lymphocytes that respond to presentation of the unmodified peptide 
did not recognize the citrullinated variant [1]. The crystallographic data directly 
demonstrates how citrullination can impact the conformation of the peptide in the 
binding groove.  
Several studies have examined T cell responses to citrullinated epitopes. 
In examining T cell responses in rats, de Haan et al. showed that T cells could 
discriminate between unmodified peptides and citrullinated peptides [2]. In 
contrast to the previous study where the impact of citrulline was in the binding 
conformation, in this case it was the TCR contacts that were changed.   
While there is substantial evidence that citrullination can have a profound 
effect on antigen presentation, our data demonstrating that T cells that 
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 exclusively respond to citrullinated protein are primed in vivo after protein 
immunization raised the question of how the epitope is modified.  
 
APC citrullinated antigen while processing for presentation.  
 
 The role of APC in citrullination of antigen has been largely ignored and 
this body of work constitutes the first direct evidence that antigen presenting cells 
can citrullinated antigen while processing for presentation. Our data demonstrate 
that APC present citrullinated peptides after processing whole unmodified HEL.  
The fundamental issue in presentation of epitopes that carry post 
translational modification is that of tolerance. The mechanism by which tolerance 
to self proteins that have been post translationally modified is unknown. Since 
citrullination is part of several normal biological processes it is clear that there 
must be some level of tolerance to citrullinated self-proteins. We show that 
thymic DC from mHEL mice present citrullinated peptides. While we have not 
addressed tolerance in this study, it is logical to conclude that thymic DC may 
play a role in establishing tolerance to some citrullinated proteins. In addition, 
constitutive, low level presentation of citrullinated peptides may have a role in 
peripheral tolerance.  
One of the strongest genetic association linked with RA is a class of MHC 
alleles that contain the so called "shared epitope", a  5 amino acid sequence, 
Q/R, K/R, R, A, and A at positions 70–74 of the β-chain in the third hypervariable 
region that forms part of the P4 pocket [3].  
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 It is this presence of these positively charged amino acids that accounts 
for the enhanced binding of peptides that carry a citrulline residue at the P4 
position, while a positively charged arginine residue hinders binding. An example 
of this was demonstrated by Hill et al. who, using transgenic mice that expressed  
HLA DRB1*0402, showed that a citrullinated peptide from vimentin bound with 
much higher affinity. They further showed that T cell responses could be 
detected in mice immunized with citrullinated self peptides, however, the focus of 
this paper was on binding and they did not carefully characterize the T cell 
specificity [4]. In a subsequent report, this group was able to show that  
immunization of these transgenic mice with citrullinated fibrinogen induced an 
arthritis-like disease [5]. In humans, found that the SE alleles predisposed 
patients to develop antibody responses to citrullinated vimentin but not fibrinogen 
[6, 7]. There are several examples of the association with SE alleles and the 
formation of anti-citrullinated protein antibody (ACPA) responses [8-16]. However 
some of the most intriguing and relevant work comes from the Toes laboratory 
which has shown that ACPA positive RA is exclusively associated with SE 
positive HLA DRB1 alleles and ACPA negative RA with HLA DRB1*03, a 
"protective" allele to be exclusively associated with ACPA negative RA [17]. 
 Collectively these data suggest that presentation of citrullinated peptides 
is playing a significant role in the development of ACPA responses that are 
associated with RA. One of the outstanding questions is how these proteins are 
citrullinated as there is no physiological role for citrullination in the function of 
most of the target proteins. Our findings introduce the additional factor of APC in 
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 citrullination of antigen especially when we consider the induced presentation of 
citrullinated peptides by B cells as discussed below. 
 
Autophagy is required for citrullination of antigen. 
 
 The evidence given here for the requirement for autophagy in citrullination 
of antigen by APC raises several intriguing points related to the role of 
autoimmune responses to citrullinated self antigen. In particular, it is interesting 
to consider the possibility that influence of the local milieu may have some 
bearing on the level of presentation of citrullinated peptides.  
In an EAE model, immunization with a citrullinated MOG peptide gave rise 
to a T cell response that included T cells that either cross reacted to unmodified 
peptide or exclusively responded to the citrullinated peptide. The mice did not 
develop EAE after transfer of T cells that only responded to the citrullinated 
peptide and induction of tolerance to the citrullinated epitope had no effect on 
disease. However, once disease was established, transfer of the citrullinated 
peptide reactive clones did exacerbate disease, indicating that the citrullinated 
peptide was presented in an inflammatory environment [18]. In a related study in 
rats, it was found that citrullinated MBP could induce disease similar to 
unmodified protein. Interestingly, in rats that had resolved disease after 
immunization with unmodified protein, secondary immunization with citrullinated 
protein induced a increase in disease severity when compared to rats that had 
been re-immunized with unmodified protein [19]. Finally, in a clinical study, it was 
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 found that T cells could recognize citrullinated myelin basic protein and that there 
are a higher number of citrullinated peptide reactive T cells in patients with 
multiple sclerosis [20].  
These results raise the question of how the disease process contributes to 
presentation of citrullinated peptides. One possibility is that the stressed 
environment induces an increase in autophagy which leads to presentation of 
citrullinated peptides.  
B cell receptor (BCR) engagement has been shown to induce autophagy 
[21, 22] as one of the many striking cellular changes that occur after antigen 
binding by B cells. Our findings that demonstrate that antigen that has been 
captured and taken up via the B cell receptor is processed through a pathway 
that allows citrullination. Furthermore, we present data that shows the BCR 
engagement with antibody leads to presentation of citrullinated peptides derived 
from endogenously expressed HEL in mHEL B cells, all of which is inhibited with 
3MA treatment. We demonstrated that the BCR localizes to an MHC and LC3 
positive compartment. This result has some significant implications.  
Beside ACPA, another serological marker for RA and other rheumatic 
diseases is rheumatoid factor (RF). It was first discovered in the 1940's with the 
observation that there were antibodies present in the sera of patients with RA 
that reacts with autologous IgG [23] [24] [25]. These antibodies are typically 
pentameric IgM and react with the fc domain of IgG, however RF has also been 
shown to bind to other isotypes of immunoglobulin, including IgM  [26]. Our 
results that show that BCR engagement by antibody induces presentation of 
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 citrullinated peptides. The combination of the presence of RF and SE containing 
HLA alleles could constitute conditions that lead to enhanced peripheral 
presentation of citrullinated self-peptides that may potentially trigger a breach of 
tolerance and lead to the initiation or enhancement of pathological adaptive 
responses. BCR induced presentation of citrullinated peptides may be the 
missing piece linking RF to RA.  
Finally, smoking has been associated with RA [27, 28] [29, 30]. 
Bronchoalveolar lavages from smokers were shown to contain higher levels of 
PAD2 expression and citrulline [31], which could stem from autophagy induced 
presentation of citrullinated peptides. The additional association of smoking as a 
risk factor for ACPA positive RA in patients with SE containing alleles is further 
evidence that supports the connection between antigen presentation and ACPA 
development [32].   
 
Future directions 
 
 The next steps in this project focus on the cellular biology of citrullination 
and the role of responses to citrullinated proteins in autoimmunity. A detailed 
understanding of the cellular mechanisms of citrullination by antigen presenting 
cells and the methods by which tolerance to citrullinated proteins can be 
breached may help to develop our understanding of diseases in which responses 
to citrullinated self-antigen could be involved.  
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 We speculate that autophagy allows entry of PAD enzymes into antigen 
loading compartments. This will be directly evaluated using a combination of 
immunofluorescence and biochemical and enzymatic analysis of subcellular 
fractions. 
Which enzymes are involved?- PAD2 and PAD4 knockout mice have been 
generated. They can be crossed on to a B10.BR background and examined for 
citrullination by APC.  
Data links single nucleotide polymorphisms in PAD4 to RA susceptibility in 
certain populations, which makes the idea that this is the key enzyme 
provocative. However it is possible that both enzymes are involved as there is 
some data in the literature that demonstrates that PAD4 can compensate for the 
loss of PAD2 [33]. Further, we will evaluate the entry of the relevant enzyme(s) in 
to an autophagic compartment by subcellular fractionation and microscopy.  
Does citrullination of antigen play a role in autoimmunity?- We have 
several reagents available to us in the form of HEL transgenic mice. In addition to 
the HEL model, our group is evaluating the role of citrullination of natural antigen 
in an EAE model.  
The role of RF in citrullination by APC will be evaluated using an RF 
transgenic mouse [34]. We show that DC in the thymus present citrullinated 
peptides in mHEL mice. We would like to extend these findings to determine if 
these APC are involved in presenting citrullinated peptides derived from blood 
borne antigen.  
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 While there remain several unanswered questions, the role of APC in 
citrullination of antigen adds a new dimension to the problem of citrullination of 
antigen. We hope that in the years to come some of the issues that have been 
raised here will be resolved.   
107 
 
 References 
1. Beltrami, A., et al., Citrullination-dependent differential presentation of a 
self-peptide by HLA-B27 subtypes. J Biol Chem, 2008. 283(40): p. 27189-
99. 
2. de Haan, E.C., et al., Limited plasticity in T cell recognition of modified T 
cell receptor contact residues in MHC class II bound peptides. Mol 
Immunol, 2005. 42(3): p. 355-64. 
3. Gregersen, P.K., J. Silver, and R.J. Winchester, The shared epitope 
hypothesis. An approach to understanding the molecular genetics of 
susceptibility to rheumatoid arthritis. Arthritis Rheum, 1987. 30(11): p. 
1205-13. 
4. Hill, J.A., et al., Cutting edge: the conversion of arginine to citrulline allows 
for a high-affinity peptide interaction with the rheumatoid arthritis-
associated HLA-DRB1*0401 MHC class II molecule. J Immunol, 2003. 
171(2): p. 538-41. 
5. Hill, J.A., et al., Arthritis induced by posttranslationally modified 
(citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med, 2008. 
205(4): p. 967-79. 
6. Verpoort, K.N., et al., Fine specificity of the anti-citrullinated protein 
antibody response is influenced by the shared epitope alleles. Arthritis 
Rheum, 2007. 56(12): p. 3949-52. 
7. Bell, D.A., J.A. Hill, and E. Cairns, An intriguing relationship between the 
immune response to citrullinated vimentin and the HLA shared epitope: 
108 
 
 comment on the article by Verpoort et al. Arthritis Rheum, 2008. 58(10): p. 
3277; author reply 3277-8. 
8. James, E.A., et al., HLA-DR1001 presents "altered-self" peptides derived 
from joint-associated proteins by accepting citrulline in three of its binding 
pockets. Arthritis Rheum. 62(10): p. 2909-18. 
9. Auger, I., et al., Influence of HLA-DR genes on the production of 
rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. 
Arthritis Rheum, 2005. 52(11): p. 3424-32. 
10. Chan, M.T., et al., Associations of erosive arthritis with anti-cyclic 
citrullinated peptide antibodies and MHC Class II alleles in systemic lupus 
erythematosus. J Rheumatol, 2008. 35(1): p. 77-83. 
11. De Rycke, L., et al., Rheumatoid factor and anticitrullinated protein 
antibodies in rheumatoid arthritis: diagnostic value, associations with 
radiological progression rate, and extra-articular manifestations. Ann 
Rheum Dis, 2004. 63(12): p. 1587-93. 
12. Feitsma, A.L., et al., Identification of citrullinated vimentin peptides as T 
cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. 
Arthritis Rheum. 62(1): p. 117-25. 
13. Hoffman, I.E., et al., Diagnostic performance and predictive value of 
rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA 
shared epitope for diagnosis of rheumatoid arthritis. Clin Chem, 2005. 
51(1): p. 261-3. 
109 
 
 14. Nijenhuis, S., et al., Autoantibodies to citrullinated proteins in rheumatoid 
arthritis: clinical performance and biochemical aspects of an RA-specific 
marker. Clin Chim Acta, 2004. 350(1-2): p. 17-34. 
15. Snir, O., et al., Multiple antibody reactivities to citrullinated antigens in sera 
from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. 
Ann Rheum Dis, 2009. 68(5): p. 736-43. 
16. Vander Cruyssen, B., et al., Anti-citrullinated protein/peptide antibodies 
(ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid 
factor. Autoimmun Rev, 2005. 4(7): p. 468-74. 
17. de Vries, R.R., T.W. Huizinga, and R.E. Toes, HLA and RA revisited: 
citrullinated food for the SE hypothesis, the DR6 effect, and NIMA. Hum 
Immunol, 2006. 67(6): p. 454-9. 
18. Carrillo-Vico, A., M.D. Leech, and S.M. Anderton, Contribution of Myelin 
Autoantigen Citrullination to T Cell Autoaggression in the CNS. J Immunol. 
19. Cao, L., D. Sun, and J.N. Whitaker, Citrullinated myelin basic protein 
induces experimental autoimmune encephalomyelitis in Lewis rats through 
a diverse T cell repertoire. J Neuroimmunol, 1998. 88(1-2): p. 21-9. 
20. Tranquill, L.R., et al., Enhanced T cell responsiveness to citrulline-
containing myelin basic protein in multiple sclerosis patients. Mult Scler, 
2000. 6(4): p. 220-5. 
21. Watanabe, K., et al., Induction of autophagy by B cell antigen receptor 
stimulation and its inhibition by costimulation. Biochem Biophys Res 
Commun, 2008. 374(2): p. 274-81. 
110 
 
 22. Watanabe, K. and T. Tsubata, Autophagy connects antigen receptor 
signaling to costimulatory signaling in B lymphocytes. Autophagy, 2009. 
5(1): p. 108-10. 
23. Waaler, E., On the occurrence of a factor in human serum activating the 
specific agglutintion of sheep blood corpuscles. 1939. APMIS, 2007. 
115(5): p. 422-38; discussion 439. 
24. Rose, H.M., C. Ragan, and et al., Differential agglutination of normal and 
sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. 
Proc Soc Exp Biol Med, 1948. 68(1): p. 1-6. 
25. Moore, T.L. and R.W. Dorner, Rheumatoid factors. Clin Biochem, 1993. 
26(2): p. 75-84. 
26. Dorner, R.W., R.L. Alexander, Jr., and T.L. Moore, Rheumatoid factors. 
Clin Chim Acta, 1987. 167(1): p. 1-21. 
27. Klareskog, L., et al., What precedes development of rheumatoid arthritis? 
Ann Rheum Dis, 2004. 63 Suppl 2: p. ii28-ii31. 
28. Padyukov, L., et al., A gene-environment interaction between smoking and 
shared epitope genes in HLA-DR provides a high risk of seropositive 
rheumatoid arthritis. Arthritis Rheum, 2004. 50(10): p. 3085-92. 
29. Huizinga, T.W., et al., Refining the complex rheumatoid arthritis phenotype 
based on specificity of the HLA-DRB1 shared epitope for antibodies to 
citrullinated proteins. Arthritis Rheum, 2005. 52(11): p. 3433-8. 
111 
 
 30. van der Woude, D., et al., Gene-environment interaction influences the 
reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. 
Nat Genet. 42(10): p. 814-6; author reply 816. 
31. Makrygiannakis, D., et al., Smoking increases peptidylarginine deiminase 
2 enzyme expression in human lungs and increases citrullination in BAL 
cells. Ann Rheum Dis, 2008. 67(10): p. 1488-92. 
32. Bang, S.Y., et al., Smoking increases rheumatoid arthritis susceptibility in 
individuals carrying the HLA-DRB1 shared epitope, regardless of 
rheumatoid factor or anti-cyclic citrullinated peptide antibody status. 
Arthritis Rheum. 62(2): p. 369-77. 
33. Raijmakers, R., et al., Experimental autoimmune encephalomyelitis 
induction in peptidylarginine deiminase 2 knockout mice. J Comp Neurol, 
2006. 498(2): p. 217-26. 
34. Sweet, R.A., et al., A new site-directed transgenic rheumatoid factor 
mouse model demonstrates extrafollicular class switch and plasmablast 
formation. Autoimmunity. 
 
 
112 
 
  
CURRICULUM VITAE 
Jamie M. Rimer (Ireland) 
10330 Concord School Rd. 
St. Louis, MO 63128 
Phone: 702-767-8674 
jamie.ireland@gmail.com 
EDUCATION 
Washington University School of Medicine, St. Louis, MO 
Enrolled 08/01/04-present 
Department of Biology and Biomedical Sciences 
Ph.D. Program Immunology 
 
University of Texas at El Paso, El Paso Texas 
Enrolled 05/01/02—07/30/04                      
College of Science 
Major: Microbiology  
Minor: Chemistry 
Degree: Bachelors of Science  
 
El Paso Community College, El Paso Texas  
Enrolled 08/01/01—05/01/02 
Pre-science 
   
RESEARCH EXPERIENCE 
 
Washington University in St. Louis, St. Louis, Missouri 
Pre-doctoral trainee. 0801/04-present 
Examine presentation of citrullinated peptides using the HEL model 
protein. 
 
University of Texas at El Paso, El Paso Texas 
Undergraduate research assistant. 05/01/02- 07/30/04 
Study pathogenicity of clinical isolates of Mycobacterium avium in a 
murine model.  
 
University of Texas at El Paso, El Paso Texas 
LSAMP summer bridge student. Summer 2002 
Assess the effect of organic compounds on T cell activation and 
death. 
 
 
113 
 
 114 
 
RESEARCH EXPERIENCE  (continued) 
 
National Institutes of Health NHLBI, Bethesda Maryland 
Summer Internship. Summer 2003 
Evaluate the role of agrin and glycosaminoglycan synthesis on the 
formation of filopodia. 
 
El Paso Community College, El Paso Texas                                                       
Laboratory Aid, mentor/tutor. 01/01/0-05/01/04 
Characterize the ecology of non-tuberculous mycobacteria in the Rio 
Grande river. 
ACHIEVEMENTS 
2006-2009- Ford Foundation Fellowship  
April 2004- Outstanding Undergraduate in Microbiology, College of Science, 
University of Texas at El Paso 
July 2004- National Dean’s List 
August 2002- Selected as a Minority Access to Research Careers (MARC) 
research fellow at the University of Texas at El Paso 
May 2002- Acceptance into the Louis Stokes Alliance for Minority Participation 
Summer Bridge Program.  
June 2002- Selected to participate in National Institutes of Health enrichment 
experience by El Paso Community College MBRS-RISE program committee. 
August 2002- Acceptance into the MBRS-RISE program at El Paso Community 
College.  
October 2003- Best oral presentation in the environmental sciences, Annual 
Biomedical Research Conference for Minority Students, San Diego, Ca 
Spring 2003- Vice-president of UTEP branch of the America Society for 
Microbiology  
April 2003- Inducted into Sigma Xi 
November 2002- Best sophomore poster presentation in the environmental 
science, Annual Biomedical Research Conference for Minority Students  
Fall 2002-  Awarded the Paso del Norte Health Foundation’s Health Oriented 
Theme research grant  
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